COPD Ischemic Heart Disease
Conditions
Interventions
None listed
Sponsors
GlaxoSmithKline
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: 1. Subjects aged >=40 years; 2. Current or former smokers with >=10 pack years; 3. Subjects attending outpatient cardiac clinic (or equivalent) fulfilling any of the following criteria: a. Documented history of an Ischemic event, b. Current diagnosis of stable IHD (including history of acute Myocardial Infarction'(MI) and angina pectoris) as diagnosed in accordance with ESC guidelines c. Receiving regular therapy for IHD for >1yr, 4. Subjects willing and able to sign study consent form.
Exclusion criteria
Exclusion criteria: 1. Subjects for whom spirometry is contraindicated (e.g. with detached retina, active tuberculosis, last trimester of pregnancy, resting pulse >120 etc); 2. Subjects with recent surgery or MI (within 1 month); lower respiratory tract infection or pneumothorax (within 2 months); or stroke (within 12 months); 3. Subjects with a pre-existing condition which, in the opinion of the investigator, would compromise the safety of the subject in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Airflow Limitation, defined by FEV1/Forced Volume Capacity (FVC) | — |
Secondary
| Measure | Time frame |
|---|---|
| • Severity of airflow limitation, as defined by GOLD stages • Restrictive airflow limitation, defined by FEV1/FVC >=0.70 and a predicted FVC | — |
Countries
Netherlands
Outcome results
None listed